Showing results (31-40 of 118) with videos related to

Sort By:
Pageof 12
Clinical Lung Cancer|October 30, 2018
Pemetrexed Continuation Maintenance Phase 3 Trials in Nonsquamous, Non-Small-Cell Lung Cancer: Focus on 2-Year Overall Survival and Continuum of CareJyoti D Patel, Luis Paz-Ares, Ralph G Zinner, et al.
Plos One|February 18, 2015
Early stage lung cancer detection in systemic sclerosis does not portend survival benefit: a cross sectional studyJeremy B Katzen, Kirtee Raparia, Rishi Agrawal, et al.
Surgical Neurology|May 11, 2005
Combination treatment of vertebral metastases using image-guided percutaneous radiofrequency ablation and vertebroplasty: a case reportRyan J Halpin, Bernard R Bendok, Kent T Sato, et al.
Cancers|July 2, 2021
Targeting the Epidermal Growth Factor Receptor in EGFR-Mutated Lung Cancer: Current and Emerging TherapiesKaram Khaddour, Sushma Jonna, Alexander Deneka, et al.
Oncotarget|October 25, 2019
Fewer actionable mutations but higher tumor mutational burden characterizes NSCLC in black patients at an urban academic medical centerNoura J Choudhury, Mansooreh Eghtesad, Sabah Kadri, et al.
Clinical Lung Cancer|December 27, 2017
Feasibility of Endobronchial Ultrasound-guided Transbronchial Needle Aspiration Cytology Specimens for Next Generation Sequencing in Non-small-cell Lung CancerSean P Stoy, Jeremy P Segal, Jeffrey Mueller, et al.
Clinical Lung Cancer|June 21, 2025
Outcomes Following First-Line Immune Checkpoint Inhibitors With or Without Chemotherapy Stratified by KRAS Mutational Status-A Real-World Analysis in Patients With Advanced NSCLCDavid J Cantor, Halla Nimeiri, Leora Horn, et al.
Clinical Lung Cancer|October 6, 2012
Importance and relevance of pulmonary symptoms among patients receiving second- and third-line treatment for advanced non-small-cell lung cancer: support for the content validity of the 4-item Pulmonary Symptom IndexSusan Magasi, Rajiv Mallick, Karen Kaiser, et al.
Archives of Pathology & Laboratory Medicine|February 28, 2014
Correlation of EGFR mutation status with predominant histologic subtype of adenocarcinoma according to the new lung adenocarcinoma classification of the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory SocietyCelina Villa, Philip T Cagle, Melissa Johnson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 13, 2009
Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancerJyoti D Patel, Thomas A Hensing, Alfred Rademaker, et al.
Pageof 12